Haptoglobin Therapeutics and Compartmentalization of Cell-Free Hemoglobin Toxicity.
haptoglobin
heme
hemoglobin
hemolysis
sepsis
sickle cell disease
subarachnoid hemorrhage
transfusion
Journal
Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
29
11
2019
revised:
17
02
2020
accepted:
18
02
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
9
7
2021
Statut:
ppublish
Résumé
Hemolysis and accumulation of cell-free hemoglobin (Hb) in the circulation or in confined tissue compartments such as the subarachnoid space is an important driver of disease. Haptoglobin is the Hb binding and clearance protein in human plasma and an efficient antagonist of Hb toxicity resulting from physiological red blood cell turnover. However, endogenous concentrations of haptoglobin are insufficient to provide protection against Hb-driven disease processes in conditions such as sickle cell anemia, sepsis, transfusion reactions, medical-device associated hemolysis, or after a subarachnoid hemorrhage. As a result, there is increasing interest in developing haptoglobin therapeutics to target 'toxic' cell-free Hb exposures. Here, we discuss key concepts of Hb toxicity and provide a perspective on the use of haptoglobin as a therapeutic protein.
Identifiants
pubmed: 32589936
pii: S1471-4914(20)30060-5
doi: 10.1016/j.molmed.2020.02.004
pii:
doi:
Substances chimiques
Haptoglobins
0
Hemoglobins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-697Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.